• Pipeline

Beta catenin program:

Building on internal drug-discovery capabilities, PRISM is advancing its beta catenin program into clinical trials in multiples disease states.

Inappropriate activation of the Wnt/β-catenin signaling pathway is observed in various tumor cells resulting in proliferation and metastasis.

The most advanced compound, PRI-724, modulates signaling of the Wnt/β-catenin signaling pathway, shifting from symmetric to asymmetric cell division resulting in a shift from proliferation towards differentiation. PRI-724 has been shown to substantially inhibit tumor growth in animal studies. In partnership with Eisai, Clinical trials in solid tumors and leukemia were initiated in US.

Dysregulation of the Wnt/β-catenin signaling pathway has also been shown to be an important factor in the fibrotic process in diseases such as hepatitis-driven cirrhosis, Idiopathic Pulmonary Fibrosis (IPF) and renal disease, as well as many skin and eye conditions. There is no effective means to reverse fibrosis, and treatment is limited to slowing disease progression. In animal models, PRI-724 has reversed the formation of excessive fibrous connective tissue, demonstrating its potential to treat fibrosis in several indications including Hepatitis C and IPF.